SLC5A2 and diabetic kidney disease: The current standard of care for DKD includes glucose and blood pressure optimization as well as the use of renin–angiotensin–aldosterone system (RAAS) blockers and more recently the use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type two diabetics [2,3].